Normal somatic growth requires the integrated function of many of the hormonal, metabolic, and other growth factors involved in the hypothalamo-pituitary-somatotrope axis. Human growth hormone (hGH) causes a variety of physiological and metabolic effects in humans and its pivotal role in postnatal growth is undisputed. Disturbances that occur during this process often cause subnormal GH secretion and/or subnormal GH sensitivity/responsiveness resulting in short stature. Despite the complexity of this linear growth process, the growth pattern of children, if evaluated in the context of normal standards, is rather predictable. Children presenting with short stature (i.e out of normal standards) are treated with daily injections of recombinant human GH (rhGH), which leads in almost all cases to an increase of height velocity. Although it is becoming more and more evident that many genes are involved in controlling the regulation of growth, the main aim of this review is to focus on the GH-1 gene, the various gene alterations and their important physiological and pathophysiological role in growth.
Introduction
Growth is an inherent property of life. The Recently, our group described a heterozygous R77C mutation in the GH molecule in a patient with growth retardation and delayed pubertal development [74] . However, the functional characterization of the GH-R77C performed through GHR binding, activation of Jak2/ Stat5 pathway, and studies of cell viability and proliferation showed no difference between wt-GH and GH-R77C [74, 75] . In contrast, reduced Signalling failure
In a short statured family documented by Ross et al., a mutation at the splice acceptor site of exon 3 resulted in a heterozygous expression of a severely truncated GHR mutant [93, 94] .
A GHR short of the cytoplasmic domain would be devoid of any signalling capacity and due to aberrant internalization, such truncated receptors accumulate at the membrane and act as dominant negative forms [94] .
Less dramatically truncated, homozygous/ compound heterozygous GHR leading to GHI have been reported [95, 96] . The truncations of the GHR were after residue 449 (nonsense sequence of residues 424-449) and 581
(nonsense sequence of residues 560-581), and in both cases caused drastically impaired Stat5 activation [97] .
Polymorphism of the GHR
A polymorphism, by definition, represents a DNA sequence variant that occurs in at least 1% of the population [98] . As far as polymorphisms Suppl, 1-125 [102, 103] . Patients with at least one GHRd3 allele (GHRfl/GHRd3; GHRd3/GHR d3) had a significantly better first year response, leading to an improved adult height on rhGH treatment than patients with homozygosity
for GHRfl [103] . However, consistency is lacking should be made to include it in future prediction models [113] .
conclusion Pharmacogenetics (impact of one gene) and pharmacogenomics (impact of several genes, genome) is the study how a person's gene/ genome can influence his/her response to medication [114] . Based on research in the field of GHD, we know that GHD is quite heterogeneous in aetiology and age at diagnosis and that improvement in adult height (over and above that of the untreated state) is the major aim of treating GHD children with rhGH [115] . The final height attained as a result of rhGH replacement therapy is influenced, in part, by the dose, injection frequency and duration of a therapy. Despite optimization of these factors, a proportion of GHD patients do not reach their target height [114, 116] .
Specifically designed and personalized, mathematical prediction models for predicting growth and final outcome of growth-promoting therapy have been proposed enabling the clinician to 'personalize' the therapy on the grounds of efficacy and economy [111] . In the future, these models may well facilitate the decision about whether the growth response to a given therapy (rhGH; rhIGF-1) in an individual child is appropriate or not [117, 118] . Based on modifiable (start of treatment, optimal dose of treatment, etc.) and non-modifiable (start heights SDS, bone age, target height SDS, etc.)
variables including genetic/genomic variants as well as phenotype-genotype relationship, the realistic growth potential should be calculated.
A computational analysis of GH variants using 
